Creative Medical Technology Announces Filing Of New US Provisional Patent Application To Expand IP Protection Surrounding Ultrasome, Its Proprietary Cell-Free Regenerative Medicine Platform

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has filed a new U.S. provisional patent application to enhance intellectual property protection for its Ultrasome™ cell-free regenerative medicine platform. This application aims to cover various aspects of the Ultrasome platform, including product composition, biological potency, manufacturing methods, and therapeutic applications, thereby strengthening the company's existing regenerative medicine IP portfolio.